246
Views
12
CrossRef citations to date
0
Altmetric
Articles

A novel vaccine delivery system: Biodegradable nanoparticles in thermosensitive hydrogel

, , , , , , , & show all
Pages 290-297 | Received 21 Jul 2011, Accepted 14 Sep 2011, Published online: 10 Oct 2011

References

  • Chong CSW, Cao M, Wong WW, Fischer KP, Addison WR, Kwon GS, Tyrrell DL, Samuel J. 2005. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release. 102:85–99.
  • Coeshott CM, Smithson SL, Verderber E, Samaniego A, Blonder JM, Rosenthal GJ, Westerink MAJ. 2004. Pluronic® F127-based systemic vaccine delivery systems. Vaccine. 22:2396–2405.
  • Gander B. 2005. Trends in particulate antigen and DNA delivery systems for vaccines. Adv Drug Deliv Rev. 57:321–323.
  • Gong C-Y, Shi S, Peng X-Y, Kan B, Yang L, Huang M-J, Luo F, Zhao X, Wei Y-Q, Qian Z-Y. Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity. Growth Factors. 2009a; 27:383.
  • Gong CY, Dong PW, Shi S, Fu SZ, Yang JL, Guo G, Zhao X, Wei YQ, Qian ZY. Thermosensitive PEG-PCL-PEG hydrogel controlled drug delivery system: Sol–gel–sol transition and in vitro drug release study. J Pharm Sci. 2009b; 98:3707–3717.
  • Gong CY, Shi S, Dong PW, Kan B, Gou ML, Wang XH, Li XY, Luo F, Zhao X, Wei Y, Qian Z. Synthesis and characterization of PEG-PCL-PEG thermosensitive hydrogel. Int J Pharm. 2009c; 365:89–99.
  • Gong CY, Shi S, Wu L, Gou ML, Yin QQ, Guo QF, Dong PW, Zhang F, Luo F, Zhao X, Wei Y, Qian Z. Biodegradable in situ gel-forming controlled drug delivery system based on thermosensitive PCL-PEG-PCL hydrogel. Part 2: Sol–gel–sol transition and drug delivery behavior. Acta Biomater. 2009d; 5:3358–3370.
  • Gou M, Dai M, Gu Y, Li X, Wen Y, Yang L, Wang K, Wei Y, Qian Z. 2008. BFGF loaded biodegradable PCL-PEG-PCL copolymeric nanoparticles: Preparation, in vitro release and immunogenicity study. J Nanosci Nanotechnol. 8:1–5.
  • Gupta RK. 1998. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 32:155–172.
  • Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. 1993. Adjuvants—a balance between toxicity and adjuvanticity. Vaccine. 11:293–306.
  • Huang Y-Y, Wang C-H. 2006. Pulmonary delivery of insulin by liposomal carriers. J Control Release. 113:9–14.
  • Jilek S, Merkle HP, Walter E. 2005. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev. 57:377–390.
  • Julie Westerink MA, Louise Smithson S, Srivastava N, Blonder J, Coeshott C, Rosenthal GJ. 2002. ProJuvantTM (Pluronic® F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine. 20:711–723.
  • Kang ML, Jiang H-L, Kang SG, Guo DD, Lee DY, Cho C-S, Yoo HS. 2007. Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine. 25:4602–4610.
  • Liu MA. 1999. Topic in review: Vaccines in the 21st century. West J Med. 171:319–322.
  • Man S, Tabi Z. 2006. Human cancer vaccines. Adv Drug Deliv Rev. 58:899–901.
  • Moll H. 2004. Antigen delivery by dendritic cells. Int J Med Microbiol. 294:337–344.
  • O'Hagan DT, Rappuoli R. Novel approaches to vaccine delivery. Pharm Res. 2004a; 21:1519–1530.
  • O'Hagan DT, Rappuoli R. The safety of vaccines. Drug Discov Today. 2004b; 9:846–854.
  • O'Hagan DT, Rappuoli R. 2006. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev. 58:29–51.
  • O'Hagan DT, Valiante NM. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov. 2:727–735.
  • O'Hagan DT, MacKichan ML, Singh M. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng. 18:69–85.
  • Peek LJ, Middaugh CR, Berkland C. 2008. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 60:915–928.
  • Poland GA, Murray D, Bonilla-Guerrero R. 2002. Science, medicine, and the future: New vaccine development. Br Med J. 324:1315–1319.
  • Singh M, O'Hagan D. 1999. Advances in vaccine adjuvants. Nat Biotech. 17:1075–1081.
  • Singh M, O'Hagan DT. 2002. Recent advances in vaccine adjuvants. Pharm Res. 19:715–728.
  • Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, O'Hagan DT. 1998. Controlled release microparticles as a single dose diphtheria toxoid vaccine: Immunogenicity in small animal models. Vaccine. 16:346–352.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.